Covid-19: Razvoj vakcine, imunitet i primena medikamenata

[dùda]

3 minutes ago, Dankan Ajdaho said:

 

 

Napisah na drugoj temi, koliko je meni poznato, niko u Srbiji ne radi test na IgG S proteine? Tako da se ne može ni videti nivo antitela (standardnim testovima).

 

Neka me ispravi neko stručniji ako grešim, ili nek uputi ko vrši ovu vrstu testiranja.

ja sam čipovana kinezom, koliko sam shvatila, radim običan igg ? 

[Dankan Ajdaho]

Hajde da zamolim @Kelt i ostale koji su u materiji neka razjasne nejasnoće u vezi merenja nivoa IgG antitela kod vakcinisanih različitim vakcinama kod nas.

 

[vememah]

14 hours ago, vememah said:

France, Poland and Sweden on Tuesday issued recommendations not to use the COVID-19 vaccine developed by AstraZeneca for the elderly.

They join Germany and Italy which issued such recommendations last week.

https://www.euronews.com/2021/02/03/france-poland-sweden-latest-eu-countries-to-rule-out-astrazeneca-jab-for-elderly

 

Danas i Grci.

 

Quote

Greece's National Vaccination Committee has unanimously approved the vaccine against the coronavirus produced by pharmaceuticals firm AstraZeneca, for those aged 64 and younger.

https://www.ekathimerini.com/262045/article/ekathimerini/news/astrazeneca-vaccine-approved-in-greece-for-people-under-65

Edited February 5, 2021 by vememah

[borris_]

Ocigledno ima neki problem sa tom vakcinom. nadam se da je problem samo u nedostatku podataka za starije.

 

Ovdje se boje da ta vakcina nije dovoljno dobra za starije (ne tvara dovoljno antitjela) i da moze u najgorem slucaju da podstakne stvaranje novih varijanata virusa. 

[Aleksija]

3 hours ago, Dankan Ajdaho said:

 

 

Napisah na drugoj temi, koliko je meni poznato, niko u Srbiji ne radi test na IgG S proteine? Tako da se ne može ni videti nivo antitela (standardnim testovima).

 

Neka me ispravi neko stručniji ako grešim, ili nek uputi ko vrši ovu vrstu testiranja.

evo opet milosa babica, naucnika mikrobiologa, iz fb grupe

Quote

Kolega mi je upravo kroz poruke poslao niz informacija iz Srbije vezano za serološke testove i vakcine; bilo je dosta pitanja u grupi na ovu temu, pa da se pokrije.

Kod inficiranih ljudi nastaju antitela na razne koronavirusne epitope koji pripadaju različitim proteinima iz virusa (epitop: meta za koju se vezuje određeno pojedinačno antitelo). Veliki broj seroloških testova meri antitela protiv nukleokapsid proteina (N proteina) . Ova antitela su češća, lakše je proizvesti test za njih (iz raznih tehničkih razloga u koje nećemo ovde ulaziti), i generalno su nestabilnija i više unakrsno reaktivna nego antitela protiv "šiljka" (S proteina). Takođe, za otpornost su važnija anti-S antitela, jer dotična sprečavaju širenje virusa unutar tela (ulazak u ćelije).

Svi testovi su otprilike jednako pouzdani, bez obzira koji epitop mere (referenca ispod). No, testovi protiv N proteina neće detektovati otpornost koju proizvode vakcine zasnovane na S proteinu. Dakle, imunitet od Pfizer, AstraZeneca, Sputnik, Novavax i sličnih vakcina neće biti "vidljiv" u takvim testovima uopšte. Imunitet od Sinopharm vakcine može biti vidljiv, ali nije sigurno.

Šta to praktično znači:

- Ako uzimate test da bi ste proverili IgG nivoe nakon preležane bolesti, bilo koji od testova je OK. Jeste, S je važniji za otpornost, ali nivo anti-N sasvim lepo očitava nivo otpornosti, i nema potrebe tu tražiti dlake u jajetu.

- Ako želite da proverite IgG nivoe nakon vakcinacije, potražite testove koji mere specifično IgG protiv S proteina. Takvih ima, reklamiraju se već kod nas, samo ih treba specifično tražiti.

 

[Kelt]

to, sve je rečeno. Čini mi se da Roche pravi IgG testove na spike

[Tsai]

Ja se ubih od guglanja i ne mogu da nadjem nijednu lab gde pise jasno igg s protein antitela, verovatno lose kucam

[vememah]

Fajzer povukao zahtev za odobravanje vakcine u Indiji zbog očekivanja da će biti odbijen.

 

 

 

 

 

[vememah]

Detaljnije:

 

Quote

NEW DELHI: The drug regulator's subject expert committee (SEC) has denied permission for emergency use authorization (EUA) to Pfizer's Covid-19 vaccine on grounds that causality of its reported adverse events are being probed and the company has not presented any plan to generate safety and immunogenicity data.
The committee – that met on Wednesday to consider the application from the US drugmaker - noted that “incidents of palsy, anaphylaxis and other SAE’s (serious adverse events) have been reported during post-marketing and the causality of the events with the vaccine is being investigated”.
“Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population. After detailed deliberation, the committee has not recommended for grant of permission for emergency use in the country at this stage,” the SEC said in its recommendations.
From the beginning, the drug regulator has maintained that any foreign company with a vaccine candidate developed outside India will have to conduct at least bridging studies in India to ensure immunogenicity.
Pfizer was the first pharma company to apply for EUA for its Covid-19 vaccine – developed with Germany’s BioNTech - in the country.
The company later said that it has decided to withdraw its application at this time and may resubmit its approval request with additional information as it becomes available in the near future.
...

https://timesofindia.indiatimes.com/india/expert-panel-had-recommended-against-granting-emergency-use-authorisation-to-pfizers-covid-vaccine-officials/articleshow/80711390.cms

[Kenji]

Ovo sa indijom mi već malo liči na zaštitu domaće industrije vakcina.

[vememah]

Quote

 

TEL AVIV HOSPITAL HAILS 'A HUGE BREAKTHROUGH'

 

New Israeli drug cured 29 of 30 moderate/serious COVID cases in days — hospital

 

Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1 trial patients left hospital within 3-5 days

 

A new coronavirus treatment being developed at Tel Aviv’s Ichilov Medical Center has successfully completed phase 1 trials and appears to have helped numerous moderate-to-serious cases of COVID-19 quickly recover from the disease, the hospital said Friday.

Hailing a “huge breakthrough,” the hospital said Prof. Nadir Arber’s EXO-CD24 substance had been administered to 30 patients whose conditions were moderate or worse, and all 30 recovered — 29 of them within three to five days.
The medicine fights the cytokine storm — a potentially lethal immune overreaction to the coronavirus infection that is believed to be responsible for much of the deaths associated with the disease.

It uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which Arber has spent decades researching.

“This protein is located on the surface of cells and has a well known and important role in regulating the immune system,” said researcher Shiran Shapira of Arber’s lab.

The protein helps calm down the immune system and curb the storm.

“The preparation is inhaled once a day for a few minutes, for five days,” Arber said. “The preparation is directed straight to the heart of the storm — the lungs — so unlike other formulas… which selectively restrain a certain cytokine, or operate widely but cause many serious side effects, EXO-CD24 is administered locally, works broadly and without side effects.”

The medicine will now move on to further trial phases, but hospital officials were already hailing it as a possible game-changer in fighting serious COVID-19 illness.

Ichilov director Roni Gamzu, the former coronavirus czar, said the research “is advanced and sophisticated and may save coronavirus patients. The results of the phase 1 trial are excellent and give us all confidence in the method [Arber] has been researching in his lab for many years.”

He added: “I am proud that at Ichilov we are… possibly bringing a blue and white remedy to a terrible global pandemic.”

 

https://www.timesofisrael.com/new-israeli-drug-cured-moderate-to-serious-covid-cases-within-days-hospital/

[vememah]

Quote

UK and CureVac agree to work on vaccines against coronavirus variants

 

The British government ordered 50 million doses as part of the deal.

German biotech company CureVac is teaming up with the U.K. to develop its next generation of vaccines against new coronavirus variants, the British government said today.

As part of the deal, the U.K. has secured 50 million doses of the new vaccines "to be delivered later this year if they are required."

CureVac said that "any resulting vaccine candidates will be manufactured and distributed in the UK and its overseas and dependent territories" if approved by regulators.

“This fantastic new partnership means we can work to swiftly tweak and rollout new variations of existing vaccines if we need to, while also building up Britain’s vaccine manufacturing base in the process,” U.K. Business Secretary Kwasi Kwarteng said in a statement.

CureVac announced earlier this week that it was teaming up with pharmaceutical giant GSK to develop the new line of vaccines. The companies said they hope to have these new vaccines on the market by 2022.

CureVac's original mRNA-based coronavirus vaccine candidate is still undergoing large-scale human trials. The EU already has a contract with the firm for 225 doses of its shot, with the option to buy another 180 million.

https://www.politico.eu/article/uk-and-curevac-agree-to-work-on-vaccines-against-coronavirus-variants/

Edited February 6, 2021 by vememah

[Moracikus]

Najnoviji rezultati sa Astrinog UK ispitivanja na osnovu sada vec 250 simptomaticnih slucajeva sto je skoro pa duplo vise nego zvanican izvjestaj u Lancetu..

Skok sa 70 na 74% efikasnosti i ocigledna djelotvornost i na britanski soj od takodje 74%.

Iako JNJ a posebno NVAX izgledaju na prvi pogled bolje ne bih bas skroz otpisao mudre glave Oksforda. Otpornost na sojeve je sada vec vaznija stavka od efikasnosti na orginalni virus.

Takodje, jedini rade asimptomaticne slucajeve i imaju preko 200 do sada.

[vememah]

13 hours ago, Moracikus said:

Najnoviji rezultati sa Astrinog UK ispitivanja na osnovu sada vec 250 simptomaticnih slucajeva sto je skoro pa duplo vise nego zvanican izvjestaj u Lancetu

 

Ostavi link sledeći put.

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160

Edited February 6, 2021 by vememah

[vememah]

Odličan članak FT o oksfordskoj vakcini - razgovarali su sa preko 30 insajdera.

 

 

Ako neće da vam otvori, probajte preko ovog Google searcha ili izbrišite kolačiće.
https://www.google.com/search?q=How+AstraZeneca’s+vaccine+was+hit+by+flawed+trials%2C+defects+and+politics+—+but+might+still+save+the+world

Edited February 6, 2021 by vememah